Search

The goal of this guidance is to contribute towards preventing as many MDR TB and XDR TB cases as possible in the EU/EEA. Given that MDR TB and XDR TB is becoming more prevalent, the issue of how to manage contacts of MDR TB patients is becoming increasingly relevant. The specific aim of this document is to provide guidance on issues relevant to the management of contacts of MDR TB and XDR TB patients.

Qualitative research was carried out in four EU countries to try to identify the factors of a healthcare system that are key to achieving good treatment results for patients with multidrug-resistant tuberculosis.

This report presents the epidemiological situation for respiratory tract infections – tuberculosis as of 2012 and describes the statistical and epidemiological methods used.

The eighth report launched jointly by ECDC and the WHO Regional Office for Europe indicates that, despite notable progress in the past decade, tuberculosis (TB) is still a public health concern in many countries across Europe.

This report describes the geographical and temporal distribution of multidrug-resistant tuberculosis based on molecular typing data (24-locus MIRU–VNTR genotyping) as reported by EU/EEA countries.

This rapid risk assessment looks at the detection of an international cluster involving 16 cases of multidrug-resistant tuberculosis in asylum seekers.

This report describes the geographical and temporal distribution of multidrug-resistant (MDR) tuberculosis (TB) using molecular typing data reported by European Union (EU)/European Economic Area (EEA) Member States for 2015 and the preceding years.

This report, the ninth report launched jointly by ECDC and the WHO Regional Office for Europe, presents the latest data on the status of tuberculosis in Europe.

This second update provides information regarding the risk of EU transmission of an MDR TB clone initially detected in seven asylum seekers from the Horn of Africa who currently reside in Switzerland.